In this article included in The Globalisation of the Pharmaceutical Industry, the authors draw on their experience to develop lessons on how to establish a sustainable life sciences eco-system in middle-income countries (MICs) and low-income countries (LICs). They highlight the importance of different types of government policy (industrial policy, the regulatory framework, intellectual property, and improving access to medicines) and how success requires different stakeholders (public and private, international and national) to work together.
To read the article, click here.
GLP-1 access is shifting – Are stakeholders ready?
CRA’s Becky Davis examines how these dramatic price reductions, combined with Direct-to-Patient distribution models, may be accelerating employer migration...